Bad blood : secrets and lies in a Silicon Valley startup

The gripping story of Elizabeth Holmes and Theranos — one of the biggest corporate frauds in history — a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. "Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” — The New York Times Book Review In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees."Crime thriller authors have nothing on Carreyrou's exquisite sense of suspenseful pacing and multifaceted character development in this riveting, read-in-one-sitting tour de force... Carreyrou's commitment to unravelling Holmes' crimes was literally of life-saving value." - Booklist The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the scandal. In 2015, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brillian Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make medical blood testing significantly faster and easier. Backed by investors such as Oracle's Larry Ellison and Tim Draper. Theranos sold shares in a fundraising round that valued the company at more that $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors and retail partners. The deception would lead to nearly one million false test results, some of which seriously jeopardized the health of patients. When John Carreyrou, a reporter at the Wall Street Journarl, started asking questions, both Carreyrou and the Journal were threatened with lawsuits, as were many of Carreyrou's sources. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero, and in March 2018, the U.S. Security and Exchange Commissioned charged Holmes with perpetrating 'an elaborte, years-long fraud'. Here is the gripping story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley 'i Couldn’t Put Down This Thriller . . . The Perfect Book To Read By The Fire This Winter.' Bill Gates, '5 Books I Loved In 2018' Winner Of The Financial Times/mckinsey Business Book Of The Year Award 2018 The Full Inside Story Of The Breathtaking Rise And Shocking Collapse Of Theranos, The Multibillion-dollar Biotech Startup, By The Prize-winning Journalist Who First Broke The Story And Pursued It To The End, Despite Pressure From Its Charismatic Ceo And Threats By Her Lawyers. In 2014, Theranos Founder And Ceo Elizabeth Holmes Was Widely Seen As The Female Steve Jobs: A Brilliant Stanford Dropout Whose Startup Unicorn Promised To Revolutionize The Medical Industry With A Machine That Would Make Blood Testing Significantly Faster And Easier. Backed By Investors Such As Larry Ellison And Tim Draper, Theranos Sold Shares In A Fundraising Round That Valued The Company At More Than $9 Billion, Putting Holmes's Worth At An Estimated $4.7 Billion. There Was Just One Problem: The Technology Didn't Work. In Bad Blood, John Carreyrou Tells The Riveting Story Of The Biggest Corporate Fraud Since Enron, A Tale Of Ambition And Hubris Set Amid The Bold Promises Of Silicon Valley. Now To Be Adapted Into A Film, With Jennifer Lawrence To Star. 'chilling . . . Reads Like A West Coast Version Of All The President’s Men.' New York Times Book Review